FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response:

0.5

	Check this box if no longer subject to							
١	Section 16. Form 4 or Form 5							
ı	obligations may continue. See							
	Instruction 1(b).							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MAYLEBEN TIMOTHY M				2. Issuer Name and Ticker or Trading Symbol Esperion Therapeutics, Inc. [ESPR]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
			-	Espection Therapeuties, Inc. [ESFR]						2	Director		10% Ov	vner		
													(give title	Other (s	specify	
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							below) below)				
C/O ESPERION THERAPEUTICS, INC.				0.	02/21/2017							President & CEO				
3891 RA	NCHERO	DRIVE, SUITE	150													
-				<u> </u>	If Ame	endment, [Date o	of Original File	ed (Month/Da	ıy/Year)	6. In	dividual or J	oint/Group Fi	ling (Check App	licable	
(Street)												Line) X Form filed by One Reporting Person				
ANN ARBOR MI 48108					2		•									
				-								Form filed by More than One Reporting Person				
(City)	(5	State)	(Zip)									1 013011				
		Та	ble I - Non-De	erivati	ve Se	curities	s Ac	quired, D	isposed c	of, or Be	neficially	Owned				
Date					2A. Deemed Execution Date Day/Year) if any (Month/Day/Yea		Code (Instr.		ed (A) or str. 3, 4 and 5	Beneficia Owned Fo	s Form (I) o ollowing (I) (In	orm: Direct D) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																
			(e.g	., puts	s, cal	ls, warr	ants	s, options,	converti	ble secu	ırities)					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		ransaction Derivative ode (Instr. Securities		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
											Amount		(Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	or Number of Shares					
Stock Option (right to buy)	\$24.42	02/21/2017		A		171,100		(1)	02/21/2027	Common Stock	171,100	\$0.00	171,100	D		

Explanation of Responses:

 $1. The options \ vest \ over \ a \ four \ (4) \ year \ period \ in \ equal \ quarterly \ installments, the \ first \ of \ which \ will \ be \ on \ May \ 21, \ 2017.$

/s/ Richard B. Bartram, by power of attorney 02/22/2017

** Signature of Reporting Person Dat

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.